SUNNYVALE, Calif., Feb. 14, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (the “Company”) (Nasdaq: PCYC) today announced that it will hold a conference call and audio webcast to discuss financial results for its fourth quarter and full year ended December 31, 2013 after the NASDAQ Market closes on Thursday, February 20, 2014 at 4:30 p.m. ET.
Conference call and webcast details:
Date: February 20, 2014
Time: 4:30 PM ET
Listen via Internet: http://ir.pharmacyclics.com/events.cfm
Toll-free: (877) 303-7908
International: (678) 373-0875
Replay Number (Toll Free): (855) 859-2056
Replay Number (International): (404) 537-3406
Conference ID #: 34406989
A webcast replay will be available on the Pharmacyclics website for 30 days.
About Pharmacyclics
Pharmacyclics® is a biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs; and to identify and control promising product candidates based on scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.
Pharmacyclics markets IMBRUVICA and has three product candidates in clinical development and several preclinical molecules in lead optimization. The company is committed to high standards of ethics, scientific rigor, and operational efficiency as it moves each of these programs to viable commercialization.
Pharmacyclics is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at www.pharmacyclics.com.
SOURCE Pharmacyclics, Inc.
Help employers find you! Check out all the jobs and post your resume.
